B
Bénédicte Gelas-Dore
Researcher at French Institute of Health and Medical Research
Publications - 6
Citations - 293
Bénédicte Gelas-Dore is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Follicular lymphoma & Ibrutinib. The author has an hindex of 5, co-authored 6 publications receiving 210 citations.
Papers
More filters
Journal ArticleDOI
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.
Emmanuel Bachy,Matthew J. Maurer,Thomas M. Habermann,Bénédicte Gelas-Dore,Delphine Maucort-Boulch,Delphine Maucort-Boulch,Jane Estell,Jane Estell,Eric Van Den Neste,Reda Bouabdallah,Emmanuel Gyan,Andrew L. Feldman,Joan Bargay,Alain Delmer,Susan L. Slager,Maria Gomes da Silva,Olivier Fitoussi,David Belada,Hervé Maisonneuve,Tanin Intragumtornchai,Stephen M. Ansell,Thierry Lamy,Peggy Dartigues,Brian K. Link,John F. Seymour,James R. Cerhan,Gilles Salles +26 more
TL;DR: The PRIMA-PI is a novel and easy-to-compute prognostic index for patients initially treated with immunochemotherapy and could serve as a basis for building more sophisticated and integrated biomolecular scores.
Journal ArticleDOI
The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association
Robert Kridel,Luc Xerri,Bénédicte Gelas-Dore,King Tan,Pierre Feugier,Ayesha Vawda,Danielle Canioni,Pedro Farinha,Sami Boussetta,Alden A. Moccia,Pauline Brice,Elizabeth A. Chavez,Alastair H. Kyle,David W. Scott,Ashley D. Sanders,Bettina Fabiani,Graham W. Slack,Andrew I. Minchinton,Corinne Haioun,Joseph M. Connors,Laurie H. Sehn,Christian Steidl,Randy D. Gascoyne,Gilles Salles +23 more
TL;DR: CD163-positive macrophages predict outcome in follicular lymphoma, but their prognostic impact is highly dependent on treatment received.
Journal ArticleDOI
Ibrutinib Monotherapy in Relapse or Refractory Primary CNS Lymphoma (PCNSL) and Primary Vitreo-Retinal Lymphoma (PVRL). Result of the Interim Analysis of the iLOC Phase II Study from the Lysa and the French LOC Network
Sylvain Choquet,Caroline Houillier,Fontanet Bijou,Roch Houot,Eileen M Boyle,Remy Gressin,Emmanuelle Nicolas-Virelizier,Maryline Barrie,Cécile Moluçon-Chabrot,Marie Blonski,Abderrazak El Yamani,Marie-Laure LeLez,Aline Clavert,Solène Coisy,Marjan Ertault de la Bretonnière,Valérie Touitou,Nathalie Cassoux,Sami Boussetta,Florence Broussais,Bénédicte Gelas-Dore,Noelie Barzic,Herve Ghesquieres,Khê Hoang-Xuan,Carole Soussain +23 more
TL;DR: Ibrutinib, an inhibitor of BCR signaling, has been found to have significant therapeutic activity in relapsed or refractory non-CNS non-GC DLBCL type and correlation of therapeutic response with mutational status of the disease is found.
Journal ArticleDOI
Rituximab treatment circumvents the prognostic impact of tumor infiltrating T-cells in follicular lymphoma patients.
Luc Xerri,Sarah Huet,Jeffrey M. Venstrom,Edith Szafer-Glusman,Bettina Fabiani,Danielle Canioni,Catherine Chassagne-Clément,Peggy Dartigues-Cuillères,Frédéric Charlotte,Camille Laurent,Bénédicte Gelas-Dore,Christopher R. Bolen,Elizabeth Punnoose,Reda Bouabdallah,Pauline Brice,Franck Morschhauser,Guillaume Cartron,Daniel Olive,Gilles Salles +18 more
TL;DR: The results suggest that the IHC prognostic value of TILs is circumvented by rituximab treatment, although there is a trend for high numbers of CD3+ Tils to correlate with better PFS.
Journal ArticleDOI
Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study
Emmanuel Bachy,Jane Estell,Eric Van Den Neste,Reda Bouabdallah,Joan Bargay,Alain Delmer,Bénédicte Gelas-Dore,Maria Gomes da Silva,Olivier Fitoussi,David Belada,Hervé Maisonneuve,Tanin Intragumtornchai,Thierry Lamy,Peggy Dartigues,John F. Seymour,Gilles Salles +15 more
TL;DR: Assessment of the outcome of follicular lymphoma patients treated in the PRIMA study with immunochemotherapy according to the use of statins concluded that statin use does not impact the prognosis of patients with follicle lymphoma treated with Immunochemotherapy.